Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 Mar;5(6):e13118.
doi: 10.14814/phy2.13118.

Peripheral venous congestion causes time- and dose-dependent release of endothelin-1 in humans

Affiliations
Randomized Controlled Trial

Peripheral venous congestion causes time- and dose-dependent release of endothelin-1 in humans

Jeffrey Lin et al. Physiol Rep. 2017 Mar.

Abstract

Endothelin-1 (ET-1) is a pivotal mediator of vasoconstriction and inflammation in congestive states such as heart failure (HF) and chronic kidney disease (CKD). Whether peripheral venous congestion (VC) increases plasma ET-1 at pressures commonly seen in HF and CKD patients is unknown. We seek to characterize whether peripheral VC promotes time- and dose-dependent increases in plasma ET-1 and whether these changes are sustained after decongestion. We used a randomized, cross-over design in 20 healthy subjects (age 30 ± 7 years). To experimentally model VC, venous pressure was increased to either 15 or 30 mmHg (randomized at first visit) above baseline by inflating a cuff around the subject's dominant arm; the nondominant arm served as a noncongested control. We measured plasma ET-1 at baseline, after 20, 60 and 120 min of VC, and finally at 180 min (60 min after cuff release and decongestion). Plasma ET-1 progressively and significantly increased over 120 min in the congested arm relative to the control arm and to baseline values. This effect was dose-dependent: ET-1 increased by 45% and 100% at VC doses of 15 and 30 mmHg, respectively (P < 0.05), and declined after 60 min of decongestion though remaining significantly elevated compared to baseline. In summary, peripheral VC causes time- and dose-dependent increases in plasma ET-1. Of note, the lower dose of 15 mmHg (more clinically relevant to HF and CKD patients) was sufficient to raise ET-1. These findings support the potentially contributory, not merely consequential, role of VC in the pathophysiology of HF and CKD.

Keywords: Congestive heart failure; endothelin; inflammation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Plasma endothelin‐1 time response to venous congestion (VC) at a dose of 15 mmHg (A) and 30 mmHg (B); 30 mmHg data at 180 min in the test arm are based on a sample of 18 subjects; 15 mmHg data at 60 min in the control arm are based on a sample of 19 subjects. * P < 0.05 versus baseline; # P < 0.05 versus control arm.
Figure 2
Figure 2
Plasma endothelin‐1 changes from baseline according to time and venous congestion (VC) dose. Change is computed as endothelin‐1 differences between each time point and baseline levels in the test arm; 30 mmHg data at 180 min in the test arm are based on a sample of 18 subjects; 15 mmHg data at 60 min in the control arm are based on a sample of 19 subjects.

References

    1. Colombo, P. C. , Onat D., Harxhi A., Demmer R. T., Hayashi Y., Jelic S., et al. 2014. Peripheral venous congestion causes inflammation, neurohormonal, and endothelial cell activation. Eur. Heart J. 35:448–454. - PMC - PubMed
    1. Cowburn, P. J. , Cleland J. G., McArthur J. D., MacLean M. R., McMurray J. J., Dargie H. J., et al. 1999. Endothelin B receptors are functionally important in mediating vasoconstriction in the systemic circulation in patients with left ventricular systolic dysfunction. J. Am. Coll. Cardiol. 33:932–938. - PubMed
    1. Cui, J. , McQuillan P. M., Blaha C., Kunselman A. R., and Sinoway L. I.. 2012. Limb venous distension evokes sympathetic activation via stimulation of the limb afferents in humans. Am. J. Physiol. Heart Circ. Physiol. 303:H457–H463. - PMC - PubMed
    1. Dhaun, N. , Melville V., Blackwell S., Talwar D. K., Johnston N. R., Goddard J., et al. 2013. Endothelin‐A receptor antagonism modifies cardiovascular risk factors in CKD. J. Am. Soc. Nephrol. 24:31–36. - PMC - PubMed
    1. Ergul, A. , Shoemaker K., Puett D., and Tackett R. L.. 1998. Gender differences in the expression of endothelin receptors in human saphenous veins in vitro. J. Pharmacol. Exp. Ther. 285:511–517. - PubMed

Publication types

LinkOut - more resources